Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 165

1.

Adjunctive aripiprazole therapy with escitalopram in patients with co-morbid major depressive disorder and alcohol dependence: clinical and neuroimaging evidence.

Han DH, Kim SM, Choi JE, Min KJ, Renshaw PF.

J Psychopharmacol. 2013 Mar;27(3):282-91. doi: 10.1177/0269881112472563. Epub 2013 Jan 16.

2.

Treatment of alcohol dependence in patients with co-morbid major depressive disorder--predictors for the outcomes with memantine and escitalopram medication.

Muhonen LH, Lahti J, Sinclair D, Lönnqvist J, Alho H.

Subst Abuse Treat Prev Policy. 2008 Oct 3;3:20. doi: 10.1186/1747-597X-3-20.

3.
4.

An open study of aripiprazole and escitalopram for psychotic major depressive disorder.

Matthews JD, Siefert C, Dording C, Denninger JW, Park L, van Nieuwenhuizen AO, Sklarsky K, Hilliker S, Homberger C, Rooney K, Fava M.

J Clin Psychopharmacol. 2009 Feb;29(1):73-6. doi: 10.1097/JCP.0b013e318193dfb4.

PMID:
19142112
5.

Adjunctive low-dose aripiprazole with standard-dose sertraline in treating fresh major depressive disorder: a randomized, double-blind, controlled study.

Lin CH, Lin SH, Jang FL.

J Clin Psychopharmacol. 2011 Oct;31(5):563-8. doi: 10.1097/JCP.0b013e31822bb0db.

PMID:
21869699
6.

Pilot study of augmentation with aripiprazole for incomplete response in late-life depression: getting to remission.

Sheffrin M, Driscoll HC, Lenze EJ, Mulsant BH, Pollock BG, Miller MD, Butters MA, Dew MA, Reynolds CF 3rd.

J Clin Psychiatry. 2009 Feb;70(2):208-13. Epub 2009 Feb 10.

7.

Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants.

Berman RM, Fava M, Thase ME, Trivedi MH, Swanink R, McQuade RD, Carson WH, Adson D, Taylor L, Hazel J, Marcus RN.

CNS Spectr. 2009 Apr;14(4):197-206.

PMID:
19407731
8.

Aripiprazole for relapse prevention and craving in alcohol-dependent subjects: results from a pilot study.

Janiri L, Martinotti G, Di Nicola M.

J Clin Psychopharmacol. 2007 Oct;27(5):519-20. No abstract available.

PMID:
17873691
9.

The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study.

Marcus RN, McQuade RD, Carson WH, Hennicken D, Fava M, Simon JS, Trivedi MH, Thase ME, Berman RM.

J Clin Psychopharmacol. 2008 Apr;28(2):156-65. doi: 10.1097/JCP.0b013e31816774f9.

PMID:
18344725
10.

Effects of aripiprazole adjunctive to standard antidepressant treatment on the core symptoms of depression: a post-hoc, pooled analysis of two large, placebo-controlled studies.

Nelson JC, Mankoski R, Baker RA, Carlson BX, Eudicone JM, Pikalov A, Tran QV, Berman RM.

J Affect Disord. 2010 Jan;120(1-3):133-40. doi: 10.1016/j.jad.2009.06.026.

PMID:
19656577
11.

The pharmacokinetics of standard antidepressants with aripiprazole as adjunctive therapy: studies in healthy subjects and in patients with major depressive disorder.

Boulton DW, Balch AH, Royzman K, Patel CG, Berman RM, Mallikaarjun S, Reeves RA.

J Psychopharmacol. 2010 Apr;24(4):537-46. doi: 10.1177/0269881108096522. Epub 2008 Oct 2.

PMID:
18832427
12.

[Escitalopram is more effective than citalopram for the treatment of severe major depressive disorder].

Azorin JM, Llorca PM, Despiegel N, Verpillat P.

Encephale. 2004 Mar-Apr;30(2):158-66. French.

PMID:
15107719
13.

Aripiprazole augmentation of selective serotonin reuptake inhibitors for treatment-resistant major depressive disorder.

Papakostas GI, Petersen TJ, Kinrys G, Burns AM, Worthington JJ, Alpert JE, Fava M, Nierenberg AA.

J Clin Psychiatry. 2005 Oct;66(10):1326-30.

PMID:
16259548
14.

The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study.

Berman RM, Marcus RN, Swanink R, McQuade RD, Carson WH, Corey-Lisle PK, Khan A.

J Clin Psychiatry. 2007 Jun;68(6):843-53.

PMID:
17592907
15.

Global benefit-risk analysis of adjunctive aripiprazole in the treatment of patients with major depressive disorder.

Wisniewski SR, Chen CC, Kim E, Kan HJ, Guo Z, Carlson BX, Tran QV, Pikalov A.

Pharmacoepidemiol Drug Saf. 2009 Oct;18(10):965-72. doi: 10.1002/pds.1805.

PMID:
19662630
16.

An open trial of aripiprazole augmentation for SSRI non-remitters with late-life depression.

Rutherford B, Sneed J, Miyazaki M, Eisenstadt R, Devanand D, Sackeim H, Roose S.

Int J Geriatr Psychiatry. 2007 Oct;22(10):986-91.

PMID:
17340654
17.
18.

Age at onset of first depressive episode as a predictor for escitalopram treatment of major depression comorbid with alcohol dependence.

Muhonen LH, Lönnqvist J, Lahti J, Alho H.

Psychiatry Res. 2009 May 15;167(1-2):115-22. doi: 10.1016/j.psychres.2008.05.001. Epub 2009 Apr 5.

PMID:
19346004
19.

Aripiprazole as adjunct to a mood stabilizer and citalopram in bipolar depression: a randomized placebo-controlled pilot study.

Quante A, Zeugmann S, Luborzewski A, Schommer N, Langosch J, Born C, Anghelescu I, Wolf J.

Hum Psychopharmacol. 2010 Mar;25(2):126-32. doi: 10.1002/hup.1096.

PMID:
20196183
20.

Supplemental Content

Support Center